European Commission approves Reblozyl (luspatercept) for treatment of transfusion-dependent anaemia associated with myelodysplastic syndromes or beta thalassaemia

Approval was based on trial which showed 37.9% of patients treated with luspatercept, the first erythroid maturation agent approved in UK & EU, achieved independence from red blood cell transfusions for at least 8 weeks during first 24 weeks of trial vs. 13.2% on placebo.